219 related articles for article (PubMed ID: 29663486)
1. Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells.
Fancy RM; Kim H; Napier T; Buchsbaum DJ; Zinn KR; Song Y
J Cell Biochem; 2018 Jul; 119(7):6216-6230. PubMed ID: 29663486
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin Binding to Death Receptor 5-mediated Death-Inducing Signaling Complex in Breast Cancer Cells.
Fancy RM; Kim H; Zhou T; Zinn KR; Buchsbaum DJ; Song Y
J Cell Biochem; 2017 Aug; 118(8):2285-2294. PubMed ID: 28092099
[TBL] [Abstract][Full Text] [Related]
3. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the Interactions between Calmodulin and Death Receptor 5 in Triple-negative and Estrogen Receptor-positive Breast Cancer Cells: AN INTEGRATED EXPERIMENTAL AND COMPUTATIONAL STUDY.
Fancy RM; Wang L; Zeng Q; Wang H; Zhou T; Buchsbaum DJ; Song Y
J Biol Chem; 2016 Jun; 291(24):12862-12870. PubMed ID: 27129269
[TBL] [Abstract][Full Text] [Related]
5. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis.
Das S; Tripathi N; Siddharth S; Nayak A; Nayak D; Sethy C; Bharatam PV; Kundu CN
Apoptosis; 2017 Oct; 22(10):1205-1224. PubMed ID: 28702823
[TBL] [Abstract][Full Text] [Related]
6. Pterostilbene Enhances TRAIL-Induced Apoptosis through the Induction of Death Receptors and Downregulation of Cell Survival Proteins in TRAIL-Resistance Triple Negative Breast Cancer Cells.
Hung CM; Liu LC; Ho CT; Lin YC; Way TD
J Agric Food Chem; 2017 Dec; 65(51):11179-11191. PubMed ID: 29164887
[TBL] [Abstract][Full Text] [Related]
7. YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.
Pennati M; Sbarra S; De Cesare M; Lopergolo A; Locatelli SL; Campi E; Daidone MG; Carlo-Stella C; Gianni AM; Zaffaroni N
Int J Cancer; 2015 Jan; 136(2):299-309. PubMed ID: 24866585
[TBL] [Abstract][Full Text] [Related]
8. Metformin sensitizes triple-negative breast cancer to proapoptotic TRAIL receptor agonists by suppressing XIAP expression.
Strekalova E; Malin D; Rajanala H; Cryns VL
Breast Cancer Res Treat; 2017 Jun; 163(3):435-447. PubMed ID: 28324269
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with anti-DR5 antibody and tamoxifen for triple negative breast cancer.
Kim H; Samuel SL; Zhai G; Rana S; Taylor M; Umphrey HR; Oelschlager DK; Buchsbaum DJ; Zinn KR
Cancer Biol Ther; 2014 Aug; 15(8):1053-60. PubMed ID: 25084100
[TBL] [Abstract][Full Text] [Related]
10. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression.
Strekalova E; Malin D; Good DM; Cryns VL
Clin Cancer Res; 2015 Jun; 21(12):2780-91. PubMed ID: 25724522
[TBL] [Abstract][Full Text] [Related]
11. PARP-1 regulates resistance of pancreatic cancer to TRAIL therapy.
Yuan K; Sun Y; Zhou T; McDonald J; Chen Y
Clin Cancer Res; 2013 Sep; 19(17):4750-9. PubMed ID: 23833311
[TBL] [Abstract][Full Text] [Related]
12. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
13. Modulation of TRAIL resistance in colon carcinoma cells: different contributions of DR4 and DR5.
van Geelen CM; Pennarun B; Le PT; de Vries EG; de Jong S
BMC Cancer; 2011 Jan; 11():39. PubMed ID: 21272366
[TBL] [Abstract][Full Text] [Related]
14. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
[TBL] [Abstract][Full Text] [Related]
15. A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5.
Wu J; Ding Y; Chen CH; Zhou Z; Ding C; Chen H; Zhou J; Chen C
Cancer Lett; 2016 Oct; 380(2):393-402. PubMed ID: 27387452
[TBL] [Abstract][Full Text] [Related]
16. Quinacrine induces apoptosis in cancer cells by forming a functional bridge between TRAIL-DR5 complex and modulating the mitochondrial intrinsic cascade.
Das S; Tripathi N; Preet R; Siddharth S; Nayak A; Bharatam PV; Kundu CN
Oncotarget; 2017 Jan; 8(1):248-267. PubMed ID: 27542249
[TBL] [Abstract][Full Text] [Related]
17. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
[TBL] [Abstract][Full Text] [Related]
18. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
[TBL] [Abstract][Full Text] [Related]
19. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
20. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.
Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ
Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
